HGBL, Nos
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma (NCT06830031) | Shanghai Exuma Biotechnology Ltd. | 2025-03-19 |
| Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma (NCT04512716) | Memorial Sloan Kettering Cancer Center | 2021-02-02 |
Track HGBL, Nos automatically
Every clearance here is in the API, with alerts when new ones post.